Pronethalol (Alderlin), an adrenergic beta-blocking agent introduced in 1963, was successfully tested in the management of various cardiac arrythmias, phaeochromocytoma, angina pectoris, and hypertension. Herring (1964) administered the drug to 10 patients with Parkinsonism, in view of the well known 'tremor-potentiating effect' of adrenaline, and observed a diminution of tremor following an intravenous dose of 50 mg.
Pronethalol (Alderlin), an adrenergic beta-blocking agent introduced in 1963, was successfully tested in the management of various cardiac arrythmias, phaeochromocytoma, angina pectoris, and hypertension. Herring (1964) administered the drug to 10 patients with Parkinsonism, in view of the well known 'tremor-potentiating effect' of adrenaline, and observed a diminution of tremor following an intravenous dose of 50 mg.
Due to the subsequent detection of carcinogenic changes in mice, although not in rats, Alderlin was withdrawn and replaced by the chemically similar, but non-toxic preparation propranolol, which was the drug employed in the present trial.
Propranolol (Inderal), 1-isopropylamino-3-(1-naphthyloxy)-2-propanol-hydrochloride, is an adrenergic, beta-receptor antagonist, having [10] [11] [12] [13] [14] [15] [16] [17] [18] [19] [20] Inderal, 5 mg. (j tablet), was given three times a day for two days, followed by daily increments of 15 mg., until a satisfactory clinical response was obtained or the daily total reached 60 mg., which was the optimal dose observed in a preliminary pilot study. If no effect was produced by 60 mg. a day for three days, the drug was discontinued.
Five patients, with moderate to severe tremor, were given 20-30 mg. of Inderal intravenously during a period of two to four minutes. Tremor was recorded with the aid of an E.E.G. apparatus, and the pulse, blood pressure, and dynamometer recordings were taken before, during, and three minutes after the end of the injection. Similar recordings were also made before and 30 minutes following oral medication.
All examinations were performed by the author alone and the symptoms and signs were evaluated clinically and/or mechanically, and graded in units of 10 from 0 (normal) to 100% (maximum severity). A number of timed performance tests were used as a measure of the patient's functional capacity. For the purpose of assessment an improvement of less than 10% was not considered significant.
All patients were normotensive and free from any symptom or sign of cardiac disease.
Routine blood, urine, and liver function studies were carried out on seven patients.
CLINICAL RESULTS
As measured by the timed performance tests, eight patients (27%) obtained a significant degree of clinical improvement from oral therapy with Inderal (10 % or more). The improvement recorded was 30 % in two patients, 20% in three, and 10% in three. Rigidity, present in 24 patients, was significantly improved in seven (30% in two, 20% in two, and 10% in three). Bradykinesia, present in 12 patients, was significantly improved in five (20% in two and 10% in three). An additional seven patients reported an improvement of rigidity and/or bradykinesia which could not be measured objectively in three, and was, as recorded by the timed performance tests, less than 10% in four. The increased strength of the 'hard-grips' was confirmed by the dynamometer in 12 patients. In no case did it exceed 30 % and was usually between 15 and 25 %.
Tremor, present in 26 patients, was significantly 404 improved in only three (20% in one, 10% in two). Subjective improvement, or a reduction of less than 10%, occurred in an additional six patients.
The drug was discontinued in 14 patients, because a daily dose of 60 mg. failed to produce any effect after three days. Several of these patients received 90 mg. daily for two to three days without significant change.
Two patients discontinued the drug due to restlessness and insomnia and one because of dizzyness. Mild degrees of headache, nausea, and dizzyness in four patients disappeared spontaneously after two to three days at an unchanged dosage level.
No direct psychostimulating or antidepressive effects were observed. A slight sedative or tranquillizing action was described by seven patients, including two of the three in whom tremor was significantly improved.
Thirty minutes after an oral dose of 20 mg. the systolic blood pressure was reduced from 10 to 20 mm. Hg in eight patients, was not significantly changed in 20, and was elevated from 10 to 20 mm. Hg in two. The pulse rate was decreased by 10 to 20 beats per minute in 14 
